NASDAQ:DFFNDiffusion Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Diffusion Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.30 +0.01 (+0.78 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$1.25Now: $1.30▼$1.3550-Day Range$0.39MA: $0.71▼$1.3552-Week Range$0.21Now: $1.30▼$3.58Volume3.69 million shsAverage Volume12.48 million shsMarket Capitalization$59.79 millionP/E RatioN/ADividend YieldN/ABeta0.81 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. was founded in 2001 and is headquartered in Charlottesville, Virginia.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDiffusion Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, Diffusion Pharmaceuticals has a potential upside of 169.2% from its current price of $1.30.Amount of Analyst CoverageDiffusion Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesDiffusion Pharmaceuticals has received 207 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDiffusion Pharmaceuticals has received 216 “underperform” votes. (Add your “underperform” vote.)Community SentimentDiffusion Pharmaceuticals has received 51.06% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Diffusion Pharmaceuticals and other stocks. Vote “Outperform” if you believe DFFN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DFFN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDiffusion Pharmaceuticals does not currently pay a dividend.Dividend GrowthDiffusion Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Diffusion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of Diffusion Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 7.15% of the stock of Diffusion Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Diffusion Pharmaceuticals are expected to grow in the coming year, from ($0.25) to ($0.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Diffusion Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Diffusion Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiffusion Pharmaceuticals has a P/B Ratio of 3.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.31 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DFFN Previous Symbol CUSIPN/A CIK1053691 Webwww.diffusionpharma.com Phone434-220-0718Debt Debt-to-Equity Ratio0.01 Current Ratio9.10 Quick Ratio9.10Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book3.33Profitability EPS (Most Recent Fiscal Year)($1.76) Net Income$-11,800,000.00 Net MarginsN/A Return on Equity-68.56% Return on Assets-57.84%Miscellaneous Employees10 Outstanding Shares45,990,000Market Cap$59.79 million Next Earnings Date8/13/2020 (Estimated) OptionableNot Optionable NASDAQ:DFFN Rates by TradingView Receive DFFN News and Ratings via Email Sign-up to receive the latest news and ratings for DFFN and its competitors with MarketBeat's FREE daily newsletter. Diffusion Pharmaceuticals (NASDAQ:DFFN) Frequently Asked Questions How has Diffusion Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Diffusion Pharmaceuticals' stock was trading at $0.3434 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DFFN stock has increased by 278.6% and is now trading at $1.30. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Diffusion Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Diffusion Pharmaceuticals. When is Diffusion Pharmaceuticals' next earnings date? Diffusion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Diffusion Pharmaceuticals. How were Diffusion Pharmaceuticals' earnings last quarter? Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) released its quarterly earnings results on Monday, May, 11th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.02. View Diffusion Pharmaceuticals' earnings history. When did Diffusion Pharmaceuticals' stock split? How did Diffusion Pharmaceuticals' stock split work? Diffusion Pharmaceuticals's stock reverse split on the morning of Friday, December 14th 2018. The 1-15 reverse split was announced on Thursday, December 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, December 13th 2018. An investor that had 100 shares of Diffusion Pharmaceuticals stock prior to the reverse split would have 7 shares after the split. What price target have analysts set for DFFN? 1 analysts have issued 12-month price targets for Diffusion Pharmaceuticals' shares. Their forecasts range from $3.50 to $3.50. On average, they expect Diffusion Pharmaceuticals' share price to reach $3.50 in the next year. This suggests a possible upside of 169.2% from the stock's current price. View analysts' price targets for Diffusion Pharmaceuticals. Has Diffusion Pharmaceuticals been receiving favorable news coverage? News coverage about DFFN stock has trended very negative on Sunday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Diffusion Pharmaceuticals earned a media sentiment score of -3.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutDiffusion Pharmaceuticals. Who are some of Diffusion Pharmaceuticals' key competitors? Some companies that are related to Diffusion Pharmaceuticals include Mallinckrodt (MNK), Hookipa Pharma (HOOK), MediciNova (MNOV), Northwest Biotherapeutics (NWBO), Inflarx (IFRX), XOMA (XOMA), Marinus Pharmaceuticals (MRNS), LifeVantage (LFVN), Iterum Therapeutics (NRBO), Aravive (ARAV), Lexicon Pharmaceuticals (LXRX), NuCana (NCNA), IVERIC bio (ISEE), Kalvista Pharmaceuticals (KALV) and IDEAYA Biosciences (IDYA). View all competitors. What other stocks do shareholders of Diffusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Amplify Energy (AMPY), Amplify Energy (AMPY), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK), Chesapeake Energy (CHK), Unum Therapeutics (UMRX), Zosano Pharma (ZSAN), ADMA Biologics (ADMA) and Miragen Therapeutics (MGEN). Who are Diffusion Pharmaceuticals' key executives? Diffusion Pharmaceuticals' management team includes the following people: Mr. David G. Kalergis, Co-Founder, CEO & Chairman (Age 70)Dr. John L. Gainer, Co-Founder, Chief Scientific Officer & Director (Age 80)Mr. William Karl Hornung, Chief Financial Officer (Age 50)Mr. Thomas E. Byrne, Gen. Counsel (Age 62)Dr. David Randolph Jones M.D., Sr. Medical Advisor (Age 56) What is Diffusion Pharmaceuticals' stock symbol? Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN." Who are Diffusion Pharmaceuticals' major shareholders? Diffusion Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.97%). Which institutional investors are buying Diffusion Pharmaceuticals stock? DFFN stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. How do I buy shares of Diffusion Pharmaceuticals? Shares of DFFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Diffusion Pharmaceuticals' stock price today? One share of DFFN stock can currently be purchased for approximately $1.30. How big of a company is Diffusion Pharmaceuticals? Diffusion Pharmaceuticals has a market capitalization of $59.79 million. The company earns $-11,800,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Diffusion Pharmaceuticals employs 10 workers across the globe. What is Diffusion Pharmaceuticals' official website? The official website for Diffusion Pharmaceuticals is www.diffusionpharma.com. How can I contact Diffusion Pharmaceuticals? Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The company can be reached via phone at 434-220-0718 or via email at [email protected] This page was last updated on 5/31/2020 by MarketBeat.com Staff
